ATS Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas William Wright
- Full Time Employees
- 7,000
- Sector
- Industrials
- Industry
- Industrial - Machinery
- Address
- Building No.2 Cambridge ON Canada N3H 4R7
- IPO Date
- Dec 29, 2009
- CIK
- 0001394832
- Website
- atsautomation.com
- Similar Companies
- Business
- ATS Corporation stands as a global leader in providing advanced automation and technology solutions. The company specializes in developing, building, commissioning, and servicing sophisticated manufacturing and assembly systems for clients worldwide. Its comprehensive offerings encompass customized automation systems, including high-precision assembly lines, robotic workcells, material handling equipment, and advanced inspection solutions integrating machine vision and artificial intelligence. Beyond system development, ATS delivers extensive value-added services. This includes a robust suite of pre-automation support such as discovery, concept development, simulation, and total cost of ownership assessments, alongside detailed engineering design, prototyping, and process verification. Post-automation services are equally comprehensive, providing training, process optimization, preventative and emergency maintenance, spare parts management, equipment retrofits, and relocation assistance to ensure sustained operational efficiency. The company also offers contract manufacturing and advanced digital solutions, featuring connected factory floor management systems designed to collect, analyze, and leverage real-time machine performance data for troubleshooting, process and product enhancements, preventing downtime, and driving sustainable production improvements. ATS Corporation serves a diverse range of critical industries, including life sciences (spanning pharmaceuticals, medical devices, and diagnostics), transportation and mobility (automotive, aerospace, and electric vehicles), consumer products, food and beverage, energy (including nuclear, oil and gas, and renewables), and electronics markets. The company was founded in 1978 and maintains its headquarters in Cambridge, Ontario, Canada. ATS has a significant global presence, operating across North America, Europe, Asia, and Oceania with over 65 manufacturing facilities and numerous offices. Recent strategic developments include the acquisition of Paxiom Group in July 2024, expanding its expertise in primary, secondary, and end-of-line packaging machinery, and the acquisition of Heidolph Instruments in August 2024, a provider of laboratory solutions. These moves bolster ATS's position in regulated industries where precision and reliability are paramount. Looking ahead, the company announced a restructuring plan in November 2025 to optimize operational efficiency, with implementation expected in fiscal 2026. ATS Corporation is listed on both the Toronto Stock Exchange (TSX) and the New York Stock Exchange (NYSE) under the ticker symbol ATS.
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS
New Strong Sell Stocks for June 29th
Implied Volatility Surging for ATS Corporation Stock Options
Fusemachines Expands Access to Agentic AI for Talent Acquisition Through Broad ATS Connectivity
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
New Strong Sell Stocks for June 15th
ATS to Participate in the Stifel Summer Solstice Conference
Securitize and Cantor Equity Partners II Announce SEC Declaration of Effectiveness of Registration Statement on Form S-4
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
ATS Q4 Earnings Call Highlights
ATS (ATS) Q4 Earnings Lag Estimates
ATS Reports Fourth Quarter Fiscal 2026 Results
Is Nordson (NDSN) 7.3% Overvalued After Q2 FY2026? GAAP EPS $2.09 (miss vs $2.57), Adj. EPS $2.86 (beat), Revenue $740.8 million (beat vs $728.84 million) -- GF Score 93/100
Securitize Reports First Quarter 2026 Results
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern
Genpact Declines 9.4% Since Beating Q1 Earnings & Revenue Estimates
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference